Diagnostic value of metagenomic next-generation sequencing of bronchoalveolar lavage fluid for the diagnosis of suspected pneumonia in immunocompromised patients.
Bronchoalveolar lavage fluid
Conventional microbiological tests
Diagnostic performance
Immunocompromised
Metagenomic next-generation sequencing
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
24
12
2021
accepted:
13
04
2022
entrez:
29
4
2022
pubmed:
30
4
2022
medline:
4
5
2022
Statut:
epublish
Résumé
To evaluate the diagnostic value of metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF) in immunocompromised patients for the diagnosis of suspected pneumonia in comparison with that of conventional microbiological tests (CMTs). Sixty-nine immunocompromised patients with suspected pneumonia received both CMTs and mNGS of BALF were analyzed retrospectively. The diagnostic value was compared between CMTs and mNGS, using the clinical composite diagnosis as the reference standard. Sixty patients were diagnosed of pneumonia including fifty-two patients with identified pathogens and eight patients with probable pathogens. Taking the composite reference standard as a gold standard, 42 pathogens were identified by CMTs including nine bacteria, 17 fungi, 8 virus, 6 Mycobacterium Tuberculosis, and two Legionella and 19(45%) of which were detected by BALF culture. As for mNGS, it identified 76 pathogens including 20 bacteria, 31 fungi, 14 virus, 5 Mycobacterium Tuberculosis, four Legionella and two Chlamydia psittaci. The overall detection rate of mNGS for pathogens were higher than that of CMTs. However, a comparable diagnostic accuracy of mNGS and CMTs were found for bacterial and viral infections. mNGS exhibited a higher diagnostic accuracy for fungal detection than CMTs (78% vs. 57%, P < 0.05), which mainly because of the high sensitivity of mNGS in patients with Pneumocystis jirovecii pneumonia (PJP) (100% vs. 28%, P < 0.05). Nineteen patients were identified as pulmonary co-infection, mNGS test showed a higher detection rate and broader spectrum for pathogen detection than that of CMTs in co-infection. Moreover, Pneumocystis jirovecii was the most common pathogen in co-infection and mNGS have identified much more co-pathogens of PJP than CMTs. mNGS of BALF improved the microbial detection rate of pathogens and exhibited remarkable advantages in detecting PJP and identifying co-infection in immunocompromised patients.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the diagnostic value of metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF) in immunocompromised patients for the diagnosis of suspected pneumonia in comparison with that of conventional microbiological tests (CMTs).
METHODS
METHODS
Sixty-nine immunocompromised patients with suspected pneumonia received both CMTs and mNGS of BALF were analyzed retrospectively. The diagnostic value was compared between CMTs and mNGS, using the clinical composite diagnosis as the reference standard.
RESULTS
RESULTS
Sixty patients were diagnosed of pneumonia including fifty-two patients with identified pathogens and eight patients with probable pathogens. Taking the composite reference standard as a gold standard, 42 pathogens were identified by CMTs including nine bacteria, 17 fungi, 8 virus, 6 Mycobacterium Tuberculosis, and two Legionella and 19(45%) of which were detected by BALF culture. As for mNGS, it identified 76 pathogens including 20 bacteria, 31 fungi, 14 virus, 5 Mycobacterium Tuberculosis, four Legionella and two Chlamydia psittaci. The overall detection rate of mNGS for pathogens were higher than that of CMTs. However, a comparable diagnostic accuracy of mNGS and CMTs were found for bacterial and viral infections. mNGS exhibited a higher diagnostic accuracy for fungal detection than CMTs (78% vs. 57%, P < 0.05), which mainly because of the high sensitivity of mNGS in patients with Pneumocystis jirovecii pneumonia (PJP) (100% vs. 28%, P < 0.05). Nineteen patients were identified as pulmonary co-infection, mNGS test showed a higher detection rate and broader spectrum for pathogen detection than that of CMTs in co-infection. Moreover, Pneumocystis jirovecii was the most common pathogen in co-infection and mNGS have identified much more co-pathogens of PJP than CMTs.
CONCLUSIONS
CONCLUSIONS
mNGS of BALF improved the microbial detection rate of pathogens and exhibited remarkable advantages in detecting PJP and identifying co-infection in immunocompromised patients.
Identifiants
pubmed: 35488253
doi: 10.1186/s12879-022-07381-8
pii: 10.1186/s12879-022-07381-8
pmc: PMC9052728
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
416Subventions
Organisme : the Project of Wenzhou Science & Technology Bureau
ID : Y20210144
Organisme : the Project of National Natural Science Foundation of China
ID : 81970066
Informations de copyright
© 2022. The Author(s).
Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
BMC Pulm Med. 2019 Dec 19;19(1):252
pubmed: 31856779
Front Cell Infect Microbiol. 2021 Mar 11;11:541092
pubmed: 33777827
Mikrobiyol Bul. 2015 Oct;49(4):484-93
pubmed: 26649406
Infect Drug Resist. 2020 Aug 13;13:2829-2836
pubmed: 32884306
Front Cell Infect Microbiol. 2018 Jun 25;8:205
pubmed: 29988504
J Infect. 2019 Jul;79(1):61-74
pubmed: 30476493
Lancet Infect Dis. 2017 Oct;17(10):1033-1041
pubmed: 28711585
Front Cell Infect Microbiol. 2021 Jun 01;11:661589
pubmed: 34141628
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Infect Dis Ther. 2021 Sep;10(3):1733-1745
pubmed: 34244957
Genome Biol. 2014;15(10):487
pubmed: 25344286
Arch Pathol Lab Med. 2017 Jun;141(6):776-786
pubmed: 28169558
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S231-S240
pubmed: 30423048
PLoS One. 2014 Oct 20;9(10):e110240
pubmed: 25329639
J Infect. 2019 Jan;78(1):75-86
pubmed: 30098322
BMC Neurol. 2021 Jun 24;21(1):236
pubmed: 34167488
J Infect. 2021 Apr;82(4):22-27
pubmed: 33609588
Clin Infect Dis. 2018 Feb 10;66(5):778-788
pubmed: 29040428
Lancet Respir Med. 2019 Feb;7(2):173-186
pubmed: 30529232
Am J Respir Crit Care Med. 2018 Jan 15;197(2):225-234
pubmed: 28846439
Pathogens. 2021 Apr 12;10(4):
pubmed: 33921275
Infect Dis Ther. 2020 Dec;9(4):1003-1015
pubmed: 33170499
Annu Rev Pathol. 2019 Jan 24;14:319-338
pubmed: 30355154